PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)

Respiratory Tract Infections Clinical Trial

— CRO-SBT  

Official title:

Efficacy and Safety of CRO-SBT Performed in Children With Acute Bacterial Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04066621
• Other study ID #: LENVOCRO (2012)CSSSI-0.4
• Status: Completed
• Phase: Phase 4
• Start date: April 28, 2015
• Est. completion date: May 27, 2017

Study information

• Verified date: August 2019
• Source: Xiangbei Welman Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting the dosage regimen for children in particular.

Description:

Ceftriaxone sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis，the latter making irreversible competitive inhibition of β-lactamase.The antimicrobial effect of Ceftriaxone can be enhanced by the two combined. The compound specifically aims to the mechanism of bacterial resistance, extending the life of Ceftriaxone in the treatment-resistant pathogen infections.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 27, 2017
• Est. primary completion date: June 11, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 14 Years

Eligibility

Inclusion Criteria:

• Male or female children ages=6 years to< 14 years.

• Weight=18kg who in hospital or outpatients with good compliance;

• The subjects were diagnosed as respiratory infection, urinary tract infection or other infection caused by the compound sensitive bacteria after clinical symptoms and signs laboratory examination and auxiliary examination according to the clinically recognized diagnostic criteria, and should be treated with systemic antibiotics;

• Subjects had not used effective antimicrobial agents before screening, or had used antimicrobial agents but the efficacy was not obvious;

• No severe liver and kidney cardiovascular and hematopoietic diseases were found in the subjects (AST and ALT were not more than 1.5 times of the upper limit of normal value,Cr was within the normal range);

• Subject guardian informed consent and/or subject's own informed consent subject volunteers to participate in this study and has signed the subject's informed consent.

Exclusion Criteria:

• History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, other ß-lactam antibiotics;

• Patients with specific infections who require treatment with other antimicrobial agents;

• Use of penicillin roxithromycin vitamin B vitamin C and other drugs may interfere with the efficacy or safety evaluation of drugs at the same time;

• Patients at risk of serious drug interactions due to combination of medications;

• Patients who have other diseases and thought to affect efficacy evaluations or be poor compliance;

• Attended clinical trial in three monthes.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Respiratory Tract Infections
• Urinary Tract Infections
• Urinary Tract Infections in Children

Intervention

Drug:
• Ceftriaxone Sodium and Sulbactam Sodium for Injection
daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xiangbei Welman Pharmaceutical Co., Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The cure rate of patients	Clinically effective/Clinically ineffective	Seven days after treatment
Secondary	bacterial clearance rate	end of treatment of bacteriological efficacy (bacterial clearance rate)	48 hours after treatment